ANALYZING THE TREATMENT COST OF LIVER CIRRHOSIS FROM HEALTHCARE PAYER'S PERSPECTIVE OF VIETNAM IN 2015

被引：1
|
作者：
Nguyen, D. K. [1 ]
Nguyen, T. T. [2 ]
Pho, N., V [1 ]
机构：
[1] Univ Med & Pharm, Ho Chi Minh City, Vietnam
[2] Univ Med & Pharm HCMC, Ho Chi Minh City, Vietnam
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.1429
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI11
引用
收藏
页码：A633 / A633
页数：1
相关论文
共 50 条
  • [31] COST OF ILLNESS OF SICKLE CELL DISEASE IN THE US, PAYER'S PERSPECTIVE: (CRESCENT)
    不详
    VALUE IN HEALTH, 2021, 24 : S202 - S202
  • [32] Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer’s Perspective
    Tingting Qu
    Shujing Zhang
    Yichen Zhong
    Yang Meng
    He Guo
    Seongjung Joo
    Peter C. Enzinger
    PharmacoEconomics, 2022, 40 : 1247 - 1259
  • [33] Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective
    Qu, Tingting
    Zhang, Shujing
    Zhong, Yichen
    Meng, Yang
    Guo, He
    Joo, Seongjung
    Enzinger, Peter C.
    PHARMACOECONOMICS, 2022, 40 (12) : 1247 - 1259
  • [34] Liver cirrhosis and complications from the perspective of dysbiosis
    Nie, Guole
    Zhang, Honglong
    Xie, Danna
    Yan, Jun
    Li, Xun
    FRONTIERS IN MEDICINE, 2024, 10
  • [35] EVOLUTION OF BREAST CANCER TREATMENT COST IN THE LAST 36 MONTHS: AN ANALYSIS FROM A HEALTH PAYER PERSPECTIVE IN BRAZIL
    Reis Neto, J. P.
    Busch, J.
    Stefani, S.
    Santos, M.
    Katz, A.
    Gondo, C. M.
    Paladini, L.
    Senra, F.
    Aguiar, Nazareth P.
    Goncalves, V
    Brust, L.
    Rocha, J.
    Nascimento Junior, R. R.
    VALUE IN HEALTH, 2023, 26 (12) : S535 - S536
  • [36] Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective
    Dakin, Helen
    Sherman, Morris
    Fung, Scott
    Fidler, Carrie
    Bentley, Anthony
    PHARMACOECONOMICS, 2011, 29 (12) : 1075 - 1091
  • [37] Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective
    Helen Dakin
    Morris Sherman
    Scott Fung
    Carrie Fidler
    Anthony Bentley
    PharmacoEconomics, 2011, 29 : 1075 - 1091
  • [38] COST EFFECTIVENESS MODEL ON FOUR PREVENTIVE TREATMENT FOR CLOSTRIDIOIDES DIFFICILE INFECTION RECURRENCE FROM A US PAYER PERSPECTIVE
    Gomez-Lumbreras, A.
    Schmutz, H.
    Tawfik, A. G.
    Malone, D. C.
    VALUE IN HEALTH, 2024, 27 (06) : S57 - S57
  • [39] COST-EFFECTIVENESS OF SOLIFENACIN FOR THE TREATMENT OF OVERACTIVE BLADDER FROM A US PRIVATE PAYER AND MEDICARE ADVANTAGE PERSPECTIVE
    Ng, D. B.
    Wielage, R.
    Klein, T. M.
    Klein, R. W.
    Gooch, K.
    VALUE IN HEALTH, 2016, 19 (07) : A519 - A519
  • [40] Comparing the cost-effectiveness of two brain metastasis treatment modalities from a payer's perspective: Stereotactic radiosurgery versus surgical resection
    Duong Anh Vuong
    Rades, Dirk
    van Eck, Albertus T. C.
    Horstmann, Gerhard A.
    Busse, Reinhard
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2013, 115 (03) : 276 - 284
12345